Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 19/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29789914 | 1.00 | MAT2A (0.52) | MAT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24596356 | 0.89 | MAT2A (0.67) | MAT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29789919 | 0.89 | MAT2A (0.67) | MAT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL30611291 | 0.87 | PDE4A (0.52) | MAT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24596154 | 0.87 | PDE4A (0.52) | MAT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24596334 | 0.85 | MAT2A (0.50) | MAT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29789910 | 0.85 | MAT2A (0.50) | MAT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24596201 | 0.85 | MAT2A (0.49) | MAT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29789948 | 0.85 | MAT2A (0.49) | MAT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24596264 | 0.83 | MAT2A (0.48) | MAT2APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124454-A1 | TRICYCLIC COMPOUND AND USE THEREOF | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-4273146-A1 | TRICYCLIC COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273146-A1 | TRICYCLIC COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| WO-2022143864-A1 | TRICYCLIC COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124454-A1 | TRICYCLIC COMPOUND AND USE THEREOF | MAT2A, MNAT1, KAT2A | MAT2A 1/4885PDE4A 1937/4885PDE4B 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.